PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Moellmann, J.* ; Klinkhammer, B.M.* ; Droste, P.* ; Kappel, B.* ; Haj-Yehia, E.* ; Maxeiner, S.* ; Artati, A. ; Adamski, J. ; Boor, P.* ; Schütt, K.* ; Lopaschuk, G.D.* ; Verma, S.* ; Marx, N.* ; Lehrke, M.*

Empagliflozin improves left ventricular diastolic function of db/db mice.

Biochim. Biophys. Acta-Mol. Basis Dis. 1866:165807 (2020)
Postprint DOI PMC
Open Access Green
Objectives: Investigation of the effect of SGLT2 inhibition by empagliflozin on left ventricular function in a model of diabetic cardiomyopathy.Background: SGLT2 inhibition is a new strategy to treat diabetes. In the EMPA-REG Outcome trial empagliflozin treatment reduced cardiovascular and overall mortality in patients with diabetes presumably due to beneficial cardiac effects, leading to reduced heart failure hospitalization. The relevant mechanisms remain currently elusive but might be mediated by a shift in cardiac substrate utilization leading to improved energetic supply to the heart.Methods: We used db/db mice on high-fat western diet with or without empagliflozin treatment as a model of severe diabetes. Left ventricular function was assessed by pressure catheter with or without dobutamine stress.Results: Treatment with empagliflozin significantly increased glycosuria, improved glucose metabolism, ameliorated left ventricular diastolic function and reduced mortality of mice. This was associated with reduced cardiac glucose concentrations and decreased calcium/calmodulin-dependent protein kinase (CaMKII) activation with subsequent less phosphorylation of the ryanodine receptor (RyR). No change of cardiac ketone bodies or branched-chain amino acid (BCAA) metabolites in serum was detected nor was cardiac expression of relevant catabolic enzymes for these substrates affected.Conclusions: In a murine model of severe diabetes empagliflozin-dependent SGLT2 inhibition improved diastolic function and reduced mortality. Improvement of diastolic function was likely mediated by reduced spontaneous diastolic sarcoplasmic reticulum (SR) calcium release but independent of changes in cardiac ketone and BCAA metabolism.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
4.352
1.181
13
19
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Empagliflozin ; Sgtl2 Inhibitors ; Cardiovascular Disease ; Type 2 Diabetes Mellitus ; Branched-chain Amino Acids ; Ketone Bodies; Heart-failure; Ketone-bodies; Inhibition; Hyperglycemia; Dysfunction; Metabolism; Mechanisms; Model
Sprache englisch
Veröffentlichungsjahr 2020
HGF-Berichtsjahr 2020
ISSN (print) / ISBN 0925-4439
e-ISSN 1878-2434
Zeitschrift Biochimica et Biophysica Acta - Molecular Basis of Disease
Quellenangaben Band: 1866, Heft: 8, Seiten: , Artikelnummer: 165807 Supplement: ,
Verlag Elsevier
Verlagsort Radarweg 29, 1043 Nx Amsterdam, Netherlands
Begutachtungsstatus Peer reviewed
Institut(e) Molekulare Endokrinologie und Metabolismus (MEM)
POF Topic(s) 30201 - Metabolic Health
Forschungsfeld(er) Genetics and Epidemiology
PSP-Element(e) G-505600-003
DOI 10.1016/j.bbadis.2020.165807
WOS ID WOS:000543299900013
Scopus ID 85084442701
PubMed ID 32353614
Erfassungsdatum 2020-06-04
[➜Korrektur melden]